Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

Open Access 01-12-2020 | COPD Exacerbation | Study protocol

Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial

Authors: Qing Kong, Shuming Mo, Wenqian Wang, Zihui Tang, Ying Wei, Yijie Du, Baojun Liu, Lingwen Kong, Yubao Lv, Jingcheng Dong

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Systemic glucocorticoids are effective for the management of chronic obstructive pulmonary disease (COPD) exacerbation but have serious adverse effects. Traditional Chinese medicine (TCM) can bring additional benefits to these patients but has few adverse effects. The present study aims to evaluate the efficacy and safety of Jia Wei Bushen Yiqi (JWBY) formulas in patients who suffer from COPD exacerbations and to investigate whether the short-term (5-days) systemic glucocorticoid therapy is non-inferior to the long-term (9-day) regime.

Methods

In this multi-center, randomized, double-blinded trial, eligible inpatients with COPD exacerbation are randomly assigned to four groups (A, B, C, and D). Group A will receive placebo plus 5-day prednisone, group B will receive placebo plus 9-day prednisone, group C will receive JWBY formulas plus 5-day prednisone, and group D will receive JWBY formulas plus 9-day prednisone. The primary outcomes are the time interval to the patient’s next exacerbation during a 180-day following up and the COPD assessment test (CAT) during treatment. Secondary outcomes include lung function, TCM syndrome assessment, laboratory tests, and safety. The changes of the hypothalamic pituitary adrenaline axis (HPA axis) and inflammatory cytokine will be measured as well.

Discussion

By demonstrating the advantages of utilizing TCM and an appropriate duration of systemic glucocorticoids, this effectiveness comparison trial will provide new references to physicians on how to improve the management of COPD exacerbation. The results of HPA axis and inflammation cytokine measurements will shed light on the molecular mechanisms and entail further mechanism studies.

Trial registration

www.​chictr.​org.​cn ChiCTR1900023364. Registered on 24 May 2019.
Appendix
Available only for authorised users
Literature
1.
2.
Wang C, Xu JY, Yang L, Xu YJ, Zhang XY, Bai CX, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health CPH study): a national cross-sectional study. Lancet. 2018;391(10131):1706–17.CrossRef
3.
Guan WJ, Ran PX, Zhong NS. Prevention and management of COPD in China: successes and major challenges. Lancet Respir Med. 2016;4(6):428–30.CrossRef
4.
Fang LW, Gao P, Bao HL, Tang X, Wang BH, Feng YJ, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–30.CrossRef
5.
Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–58.CrossRef
6.
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–50.CrossRef
7.
Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.CrossRef
8.
Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–72.CrossRef
9.
Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35(1):157–63.CrossRef
10.
Cai BQ, Cai SX, Chen RC, Cui LY, Feng YL, Gu YT, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis. 2014;9:381–95.PubMedPubMedCentral
11.
Marcos PJ, Nieto-Codesido I, de Jorge Dominguez-Pazos S, Huerta A, Marquez E, Maiso A, et al. Treatment with systemic steroids in severe chronic obstructive pulmonary disease exacerbations: use of short regimens in routine clinical practice and their impact on hospital stay. Arch Bronconeumol. 2017;53(11):611–5.CrossRef
12.
Wedzicha JA, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):16.CrossRef
13.
Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, et al. Revised (2018) COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis. 2018;81(4):261–73.CrossRef
14.
Stolz D, Barandun J, Borer H, Bridevaux PO, Brun P, Brutsche M, et al. Diagnosis, prevention and treatment of stable COPD and acute exacerbations of COPD: the Swiss Recommendations 2018. Respiration. 2018;96(4):382–98.CrossRef
15.
Zhang J, Zheng J, Huang K, Chen Y, Yang J, Yao W. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12.
16.
Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154(2):407–12.CrossRef
17.
Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177):456–60.CrossRef
18.
Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1941–7.CrossRef
19.
de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, van den Berg JWK. Oral or IV prednisolone in the treatment of COPD exacerbations - a randomized, controlled, double-blind study. Chest. 2007;132(6):1741–7.CrossRef
20.
Alia I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med. 2011;171(21):1939–46.CrossRef
21.
Abroug F, Ouanes I, Abroug S, Dachraoui F, Ben Abdallah S, Hammouda Z, et al. Systemic corticosteroids in acute exacerbation of COPD: a meta-analysis of controlled studies with emphasis on ICU patients. Ann Intensive Care. 2014;4:11.CrossRef
22.
Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F, et al. Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J. 2014;43(3):717–24.CrossRef
23.
Adcock IM, Mumby S. Glucocorticoids. Pharmacol Ther Asthma COPD. 2017;237:171–96.CrossRef
24.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019.
25.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Muellerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.CrossRef
26.
Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71.CrossRef
27.
Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.CrossRef
28.
Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV (1) - the Lung Health Study. JAMA. 1994;272(19):1497–505.CrossRef
29.
Wang YH, Xu AL. Zheng: a systems biology approach to diagnosis and treatments. Science. 2014;346(6216):S13–S5.
30.
An X, Zhang AL, May BH, Lin L, Xu Y, Xue CC. Oral Chinese herbal medicine for improvement of quality of life in patients with stable chronic obstructive pulmonary disease: a systematic review. J Altern Complement Med. 2012;18(8):731–43.CrossRef
31.
Kinoshita M, Lee SH, Hang L-W, Ichinose M, Hosoe M, Okino N, et al. Efficacy and safety of indacaterol 150 and 300 mu g in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012;17(2):379–89.CrossRef
32.
Li J-S, Li S-Y, Yu X-Q, Xie Y, Wang M-H, Li Z-G, et al. Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-centre study. J Ethnopharmacol. 2012;141(2):584–91.CrossRef
33.
S-y L, J-s L, Wang M-h, Xie Y, Yu X-Q, Sun Z-K, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-centre, open-label, randomized, controlled study. BMC Complement Altern Med. 2012;12.
34.
Ma JF, Zheng JP, Zhong NS, Bai CX, Wang HY, Du J, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2018;13:3107–14.CrossRef
35.
Wang G, Liu B, Cao Y, Du Y, Zhang H, Luo Q, et al. Effects of two chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicentre, double-blind, randomized controlled trial. PLoS One. 2014;9(8):e103168.CrossRef
36.
Shen ZY, Dong JC, Cai DF. Important action of improving adrenocortical function for certain diseases recovery. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007;27(4):364–7.PubMed
37.
Lu LL. Effect and mechanism of several traditional Chinese medicine components on inflammatory response of chronic obstructive pulmonary disease caused by exposure to cigarette smoke [PhD dissertation]: Fudan University; 2012.
38.
Xu F, Lin J, Cui W, Kong Q, Li Q, Li L, et al. Scutellaria baicalensis attenuates airway remodeling via PI3K/Akt/NF-kappaB pathway in cigarette smoke mediated-COPD rats model. Evid Based Complement Alternat Med. 2018;2018:1281420.PubMedPubMedCentral
39.
Liu MH, Lin AH, Lee HF, Ko HK, Lee TS, Kou YR. Paeonol attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling. Mediat Inflamm. 2014;2014:651890.
40.
Xu F, Cui W, Kong Q, Tang Z, Dong J. A real-world evidence study for distribution of traditional Chinese medicine syndrome and its elements on respiratory disease. Evid Based Complement Alternat Med. 2018;2018:8305892.PubMedPubMedCentral
41.
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31.CrossRef
42.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.CrossRef
43.
Chan A-W TJ, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRef
Metadata
Title
Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial
Authors
Qing Kong
Shuming Mo
Wenqian Wang
Zihui Tang
Ying Wei
Yijie Du
Baojun Liu
Lingwen Kong
Yubao Lv
Jingcheng Dong
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04669-5

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Study protocol

The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial

Study protocol

Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study

Study protocol

Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725)

Study protocol

Aim2Be mHealth intervention for children with overweight and obesity: study protocol for a randomized controlled trial

Study protocol

Efficacy of acupuncture at three nasal acupoints plus acupoint application for perennial allergic rhinitis: A multicenter, randomized controlled trial protocol

Commentary

Cluster randomised trials of prescribing policy: an ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method